Globus Medical (GMED) Financials

$58.70 -0.52 (-0.87%)

As of 02:53 PM Eastern

Annual Income Statements for Globus Medical

This table shows Globus Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	103	123	190	149	102	155	156	107	104	113
Consolidated Net Income / (Loss)	103	123	190	149	102	155	156	107	104	113
Net Income / (Loss) Continuing Operations	103	123	190	149	102	155	156	107	104	113
Total Pre-Tax Income	121	165	243	180	126	190	189	170	157	173
Total Operating Income	166	133	228	172	111	172	169	162	154	172
Total Gross Profit	1,484	1,020	759	719	572	605	554	486	429	412
Total Revenue	2,519	1,568	1,023	958	789	785	713	636	564	545
Operating Revenue	2,519	1,568	1,023	958	789	785	713	636	564	545
Total Cost of Revenue	1,035	548	264	239	217	180	159	150	135	132
Operating Cost of Revenue	1,035	548	264	239	217	180	159	150	135	132
Total Operating Expenses	1,318	887	531	547	460	433	384	324	275	240
Selling, General & Admin Expense	981	643	432	408	355	355	312	268	222	210
Research & Development Expense	164	124	73	97	85	60	55	44	45	36
Amortization Expense	119	51	18	19	17	14	9.59	7.91	3.48	1.56
Restructuring Charge	53	68	5.96	17	4.03	2.58	1.68	1.61	1.83	3.35
Other Special Charges / (Income)	0.31	0.43	2.34	5.92	0.01	2.19	5.88	2.67	3.16	-11
Total Other Income / (Expense), net	-45	32	15	8.45	14	18	19	8.09	3.14	1.17
Interest Expense	4.19	-20	-14	-9.30	-14	-17	-13	-6.61	-3.06	-1.30
Other Income / (Expense), net	-41	12	0.84	-0.84	0.51	0.55	6.00	1.48	0.08	-0.14
Income Tax Expense	18	43	53	31	24	35	32	63	53	60
Basic Earnings per Share	$0.76	$1.09	$1.89	$1.48	$1.04	$1.57	$1.60	$1.12	$1.09	$1.19
Weighted Average Basic Shares Outstanding	135.73M	113.09M	100.47M	100.73M	98.58M	99.15M	97.88M	96.24M	95.65M	95.05M
Diluted Earnings per Share	$0.75	$1.07	$1.85	$1.44	$1.01	$1.52	$1.54	$1.10	$1.08	$1.17
Weighted Average Diluted Shares Outstanding	137.86M	114.63M	102.64M	103.62M	100.97M	102.00M	101.32M	97.89M	96.43M	96.07M
Weighted Average Basic & Diluted Shares Outstanding	137.54M	135.37M	100.30M	101.56M	99.80M	99.84M	97.80M	95.80M	95.70M	94.80M

This table shows Globus Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	75	27	52	32	-7.12	15	1.00	58	49	50	47
Consolidated Net Income / (Loss)	75	27	52	32	-7.12	15	1.00	58	49	50	47
Net Income / (Loss) Continuing Operations	75	27	52	32	-7.12	15	1.00	58	49	50	47
Total Pre-Tax Income	104	25	57	48	-8.56	25	2.54	75	63	62	61
Total Operating Income	97	60	48	50	8.00	10	0.40	66	56	54	60
Total Gross Profit	403	394	355	370	365	351	248	215	206	204	189
Total Revenue	598	657	626	630	607	617	384	292	277	274	254
Operating Revenue	598	657	626	630	607	617	384	292	277	274	254
Total Cost of Revenue	195	263	271	260	241	265	135	76	71	71	65
Operating Cost of Revenue	195	263	271	260	241	265	135	76	71	71	65
Total Operating Expenses	306	334	307	320	357	341	248	149	149	150	129
Selling, General & Admin Expense	243	253	241	238	249	245	156	120	122	118	107
Research & Development Expense	33	33	35	38	57	52	29	21	21	20	19
Amortization Expense	29	30	30	30	30	28	14	4.55	4.60	4.51	4.32
Restructuring Charge	1.06	17	1.57	13	22	16	46	5.71	1.36	7.79	-0.65
Total Other Income / (Expense), net	6.66	-36	8.93	-2.04	-17	15	2.13	8.46	6.79	8.39	1.76
Interest Expense	-1.68	-0.82	0.78	2.34	1.89	2.58	-7.92	-8.29	-6.50	-5.32	-3.90
Other Income / (Expense), net	4.98	-36	9.71	0.29	-15	17	-5.79	0.17	0.29	3.07	-2.14
Income Tax Expense	28	-1.84	5.20	16	-1.44	9.96	1.54	17	14	12	14
Basic Earnings per Share	$0.55	$0.20	$0.38	$0.23	($0.05)	$0.02	$0.01	$0.57	$0.49	$0.50	$0.48
Weighted Average Basic Shares Outstanding	136.76M	135.73M	135.62M	135.20M	135.36M	113.09M	113.54M	100.37M	100.28M	100.47M	99.65M
Diluted Earnings per Share	$0.54	$0.19	$0.38	$0.23	($0.05)	$0.01	$0.01	$0.57	$0.48	$0.48	$0.47
Weighted Average Diluted Shares Outstanding	139.77M	137.86M	138.06M	136.98M	135.36M	114.63M	115.25M	101.78M	102.20M	102.64M	101.42M
Weighted Average Basic & Diluted Shares Outstanding	135.38M	137.54M	136.17M	135.41M	135.06M	135.37M	137.79M	100.46M	100.33M	100.30M	99.84M

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	317	317	-43	-46	44	56	21	51	-16	-25
Net Cash From Operating Activities	521	243	178	276	199	172	182	159	148	124
Net Cash From Continuing Operating Activities	521	243	178	276	199	172	182	159	148	124
Net Income / (Loss) Continuing Operations	103	123	190	149	102	155	156	107	104	113
Consolidated Net Income / (Loss)	103	123	190	149	102	155	156	107	104	113
Depreciation Expense	254	145	68	70	63	53	42	42	39	24
Amortization Expense	241	81	5.39	2.78	0.59	-1.09	1.68	2.67	4.07	3.35
Non-Cash Adjustments To Reconcile Net Income	119	52	37	72	72	32	30	28	24	9.87
Changes in Operating Assets and Liabilities, net	-197	-157	-122	-18	-39	-67	-48	-21	-23	-26
Net Cash From Investing Activities	-176	303	-110	-376	-117	-140	-193	-111	-163	-153
Net Cash From Continuing Investing Activities	-176	303	-110	-376	-117	-140	-193	-111	-163	-153
Purchase of Property, Plant & Equipment	-115	-78	-74	-57	-64	-71	-60	-51	-41	-51
Acquisitions	-18	-296	-31	-34	-33	-24	-15	-30	-76	-49
Purchase of Investments	-114	-101	-420	-622	-224	-347	-538	-393	-350	-300
Sale and/or Maturity of Investments	71	778	415	338	203	301	384	363	335	246
Net Cash From Financing Activities	-28	-232	-110	54	-39	24	33	1.63	0.47	4.28
Net Cash From Continuing Financing Activities	-28	-232	-110	54	-39	24	33	1.63	0.47	4.28
Repurchase of Common Equity	-86	-226	-144	0.00	-105	0.00	0.00	-	-	-
Other Financing Activities, net	58	-6.26	35	54	66	24	33	1.63	0.47	4.28
Effect of Exchange Rate Changes	0.26	2.18	-0.75	-0.81	0.87	-0.16	-	1.98	-1.89	0.15
Cash Income Taxes Paid	159	101	78	45	25	34	31	59	50	57

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-323	162	212	56	-113	188	-27	89	67	16	-17
Net Cash From Operating Activities	177	210	204	54	52	105	50	35	53	64	33
Net Cash From Continuing Operating Activities	177	210	204	54	52	105	50	35	53	64	33
Net Income / (Loss) Continuing Operations	75	27	52	32	-7.12	15	1.00	58	49	50	47
Consolidated Net Income / (Loss)	75	27	52	32	-7.12	15	1.00	58	49	50	47
Depreciation Expense	66	68	67	64	55	71	37	18	18	17	18
Amortization Expense	6.29	53	67	60	60	61	19	0.30	0.48	0.94	1.24
Non-Cash Adjustments To Reconcile Net Income	19	50	14	23	32	1.84	28	11	11	8.99	9.39
Changes in Operating Assets and Liabilities, net	10	12	3.28	-124	-88	-44	-35	-52	-26	-13	-43
Net Cash From Investing Activities	131	-104	-15	-10	-47	321	-81	52	11	-60	-63
Net Cash From Continuing Investing Activities	131	-104	-15	-10	-47	321	-81	52	11	-60	-63
Purchase of Property, Plant & Equipment	-36	-17	-42	-28	-29	-23	-22	-18	-16	-18	-12
Acquisitions	-5.00	-	-0.10	-4.89	-13	-	-293	-	-2.66	-30	-
Purchase of Investments	-1.75	-100	-1.19	-4.16	-8.02	-	-19	-12	-69	-97	-143
Sale and/or Maturity of Investments	174	13	28	26	2.65	343	253	82	99	86	92
Net Cash From Financing Activities	-635	60	20	8.71	-116	-237	1.43	1.08	2.94	14	13
Net Cash From Continuing Financing Activities	-635	60	20	8.71	-116	-237	1.43	1.08	2.94	14	13
Repayment of Debt	-450	-	-	-	-	-	-	-	-	-	-
Repurchase of Common Equity	-190	-1.00	-	-1.47	-83	-226	-	-	0.00	-	-
Other Financing Activities, net	5.04	61	20	10	-32	-12	1.43	1.08	2.94	14	13
Effect of Exchange Rate Changes	3.54	-4.28	4.07	3.77	-3.31	-0.35	2.12	0.43	-0.03	-0.84	0.48
Cash Income Taxes Paid	7.20	41	46	70	1.97	35	26	37	1.72	20	22

This table presents Globus Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	5,252	5,086	2,076	1,957	1,679	1,532	1,301	1,079	928	834
Total Current Assets	2,177	1,915	983	865	822	687	631	620	514	545
Cash & Equivalents	784	467	150	193	-	-	-	-	67	60
Short-Term Investments	106	50	296	250	187	116	200	255	223	221
Accounts Receivable	558	503	213	164	142	154	137	117	92	78
Inventories, net	659	848	299	237	229	196	131	108	113	105
Prepaid Expenses	50	45	21	18	18	17	15	11	15	7.35
Current Deferred & Refundable Income Taxes	21	1.64	4.06	1.22	6.42	8.10	7.29	8.72	3.80	47
Plant, Property, & Equipment, net	562	587	244	221	217	200	172	143	124	115
Total Noncurrent Assets	2,513	2,584	849	872	641	645	498	315	290	175
Long-Term Investments	66	75	496	562	359	410	263	56	60	49
Goodwill	1,432	1,435	197	180	157	129	124	124	106	92
Intangible Assets	795	925	64	69	87	79	87	79	62	33
Noncurrent Deferred & Refundable Income Taxes	94	11	49	24	6.62	5.93	14	20	31	0.00
Other Noncurrent Operating Assets	125	139	43	36	32	22	10	7.95	0.93	0.59
Total Liabilities & Shareholders' Equity	5,252	5,086	2,076	1,957	1,679	1,532	1,301	1,079	928	834
Total Liabilities	1,074	1,088	230	216	173	130	115	111	96	119
Total Current Liabilities	856	392	159	140	121	111	96	93	80	83
Short-Term Debt	443	0.00	-	-	-	-	-	-	-	-
Accounts Payable	75	57	36	22	18	25	26	25	17	16
Accrued Expenses	261	240	92	91	78	63	60	53	46	54
Current Deferred Revenue	22	18	14	12	8.13	5.40	2.60	0.76	0.00	-
Current Deferred & Payable Income Tax Liabilities	11	3.85	0.99	1.05	1.10	1.06	0.92	3.27	1.91	0.76
Other Current Liabilities	44	73	16	14	15	17	6.83	11	14	12
Total Noncurrent Liabilities	219	696	71	76	52	18	19	18	16	36
Long-Term Debt	0.00	417	0.00	-	-	-	-	-	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	24	84	1.78	4.31	6.20	6.02	8.11	11	7.88	13
Other Noncurrent Operating Liabilities	195	194	69	71	46	12	11	6.98	7.79	23
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	4,177	3,998	1,846	1,741	1,506	1,402	1,186	968	832	715
Total Preferred & Common Equity	4,177	3,998	1,846	1,741	1,506	1,402	1,186	968	832	715
Total Common Equity	4,177	3,998	1,846	1,741	1,506	1,402	1,186	968	832	715
Common Stock	3,031	2,871	631	554	457	357	300	238	212	193
Retained Earnings	1,153	1,137	1,240	1,194	1,045	1,048	893	736	629	525
Accumulated Other Comprehensive Income / (Loss)	-6.86	-10	-25	-6.77	3.96	-2.90	-7.17	-6.91	-8.64	-1.96

This table presents Globus Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	4,711	5,086	4,994	4,944	5,356	2,212	2,150	1,977
Total Current Assets	1,710	2,057	1,924	1,829	1,917	1,210	1,070	920
Cash & Equivalents	461	623	410	354	280	306	218	134
Short-Term Investments	0.00	72	83	80	189	306	287	271
Accounts Receivable	535	588	612	534	494	240	223	206
Inventories, net	664	718	770	816	905	336	321	282
Prepaid Expenses	47	51	46	43	48	20	19	24
Current Deferred & Refundable Income Taxes	3.02	5.15	2.50	0.37	1.74	1.76	3.04	2.20
Plant, Property, & Equipment, net	556	568	572	579	607	248	245	236
Total Noncurrent Assets	2,445	2,462	2,498	2,536	2,832	754	834	820
Long-Term Investments	0.00	12	28	51	276	392	480	504
Goodwill	1,433	1,432	1,454	1,451	1,122	199	199	182
Intangible Assets	772	843	867	888	1,262	55	59	54
Noncurrent Deferred & Refundable Income Taxes	117	45	18	11	7.32	62	51	45
Other Noncurrent Operating Assets	123	129	131	135	164	47	45	36
Total Liabilities & Shareholders' Equity	4,711	5,086	4,994	4,944	5,356	2,212	2,150	1,977
Total Liabilities	623	1,017	1,017	1,021	1,169	227	235	212
Total Current Liabilities	385	818	794	786	429	155	168	145
Short-Term Debt	0.00	437	430	424	-	-	-	-
Accounts Payable	73	58	67	50	87	34	40	32
Accrued Expenses	238	255	216	210	222	90	84	88
Current Deferred Revenue	17	21	20	17	18	15	14	12
Current Deferred & Payable Income Tax Liabilities	13	4.17	11	43	34	1.76	16	1.31
Other Current Liabilities	44	43	49	42	68	15	14	11
Total Noncurrent Liabilities	238	199	223	235	740	72	67	67
Noncurrent Deferred & Payable Income Tax Liabilities	47	7.48	27	40	132	5.30	1.37	1.58
Other Noncurrent Operating Liabilities	192	191	196	195	198	67	66	66
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	4,088	4,069	3,976	3,922	4,187	1,985	1,915	1,764
Total Preferred & Common Equity	4,088	4,069	3,976	3,922	4,187	1,985	1,915	1,764
Total Common Equity	4,088	4,069	3,976	3,922	4,187	1,985	1,915	1,764
Common Stock	3,054	2,950	2,914	2,887	2,858	657	645	606
Retained Earnings	1,036	1,126	1,074	1,047	1,348	1,347	1,289	1,190
Accumulated Other Comprehensive Income / (Loss)	-2.17	-6.96	-12	-11	-19	-19	-19	-32

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	60.62%	53.34%	6.76%	21.43%	0.47%	10.15%	12.11%	12.76%	3.53%	14.84%
EBITDA Growth	67.38%	22.55%	24.07%	38.97%	-21.76%	2.54%	5.08%	5.58%	-1.23%	22.74%
EBIT Growth	-14.01%	-36.51%	33.71%	52.85%	-35.12%	-1.59%	7.35%	5.90%	-10.38%	24.59%
NOPAT Growth	43.16%	-44.55%	25.44%	57.07%	-35.58%	0.04%	37.40%	-0.02%	-9.02%	21.78%
Net Income Growth	-16.19%	-35.39%	27.47%	45.86%	-34.10%	-0.81%	45.76%	2.88%	-7.49%	21.95%
EPS Growth	-29.91%	-42.16%	28.47%	42.57%	-33.55%	-1.30%	40.00%	1.85%	-7.69%	20.62%
Operating Cash Flow Growth	113.82%	36.44%	-35.40%	38.98%	15.59%	-5.32%	14.20%	7.60%	19.21%	56.63%
Free Cash Flow Firm Growth	110.62%	-30,147.99%	-92.66%	150.77%	21.89%	-56.32%	111.98%	335.48%	-273.93%	-64.64%
Invested Capital Growth	-4.12%	322.59%	22.98%	2.00%	5.81%	16.94%	8.32%	11.87%	33.79%	39.29%
Revenue Q/Q Growth	1.64%	27.89%	2.45%	1.76%	2.84%	2.04%	2.87%	4.00%	1.62%	2.60%
EBITDA Q/Q Growth	-2.21%	29.58%	14.90%	-14.40%	7.86%	4.03%	-0.99%	1.91%	-4.96%	9.84%
EBIT Q/Q Growth	-2.90%	-16.89%	20.68%	-19.55%	9.24%	3.94%	-2.92%	8.96%	-12.03%	10.79%
NOPAT Q/Q Growth	61.69%	-28.35%	20.08%	-20.23%	9.64%	6.35%	7.07%	-0.47%	-11.77%	9.45%
Net Income Q/Q Growth	12.53%	-22.18%	22.52%	-20.24%	7.83%	6.00%	8.59%	0.07%	-11.31%	9.69%
EPS Q/Q Growth	31.58%	-30.52%	21.71%	-20.88%	10.99%	4.83%	7.69%	0.00%	-10.74%	8.33%
Operating Cash Flow Q/Q Growth	25.46%	20.07%	-6.44%	-1.40%	14.96%	6.19%	-0.30%	13.16%	-11.81%	55.35%
Free Cash Flow Firm Q/Q Growth	113.52%	1.41%	-65.20%	-27.80%	59.00%	-16.74%	35.90%	-11.95%	16.51%	129.26%
Invested Capital Q/Q Growth	-3.55%	-0.78%	5.80%	0.30%	-1.50%	0.00%	-2.80%	-0.15%	-1.32%	3.16%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	58.90%	65.05%	74.22%	75.03%	72.44%	77.08%	77.64%	76.34%	76.12%	75.71%
EBITDA Margin	24.62%	23.63%	29.57%	25.44%	22.23%	28.55%	30.67%	32.71%	34.94%	36.63%
Operating Margin	6.59%	8.49%	22.29%	17.95%	14.12%	21.90%	23.75%	25.45%	27.33%	31.61%
EBIT Margin	4.96%	9.26%	22.37%	17.86%	14.19%	21.97%	24.59%	25.68%	27.34%	31.59%
Profit (Net Income) Margin	4.09%	7.83%	18.59%	15.57%	12.96%	19.76%	21.95%	16.88%	18.50%	20.70%
Tax Burden Percent	85.31%	74.29%	78.25%	82.70%	81.24%	81.71%	82.96%	63.17%	66.34%	65.27%
Interest Burden Percent	96.65%	113.86%	106.22%	105.43%	112.46%	110.09%	107.57%	104.05%	101.98%	100.42%
Effective Tax Rate	14.69%	25.71%	21.75%	17.30%	18.76%	18.29%	17.04%	36.83%	33.66%	34.73%
Return on Invested Capital (ROIC)	3.78%	4.19%	21.75%	19.53%	12.91%	22.23%	25.07%	20.07%	24.34%	36.41%
ROIC Less NNEP Spread (ROIC-NNEP)	15.00%	-0.10%	20.54%	18.75%	11.35%	20.02%	21.97%	18.76%	23.75%	36.30%
Return on Net Nonoperating Assets (RNNOA)	-1.26%	0.02%	-11.15%	-10.34%	-5.88%	-10.24%	-10.54%	-8.14%	-10.85%	-19.07%
Return on Equity (ROE)	2.52%	4.20%	10.60%	9.19%	7.03%	11.99%	14.53%	11.93%	13.49%	17.34%
Cash Return on Invested Capital (CROIC)	7.99%	-119.27%	1.14%	17.54%	7.27%	6.61%	17.08%	8.86%	-4.56%	3.57%
Operating Return on Assets (OROA)	2.42%	4.06%	11.34%	9.41%	6.97%	12.18%	14.74%	16.28%	17.51%	22.38%
Return on Assets (ROA)	1.99%	3.43%	9.43%	8.20%	6.37%	10.96%	13.15%	10.70%	11.85%	14.67%
Return on Common Equity (ROCE)	2.52%	4.20%	10.60%	9.19%	7.03%	11.99%	14.53%	11.93%	13.48%	17.34%
Return on Equity Simple (ROE_SIMPLE)	2.47%	3.07%	10.30%	8.57%	6.79%	11.07%	13.20%	11.09%	12.54%	15.77%
Net Operating Profit after Tax (NOPAT)	142	99	178	142	91	141	140	102	102	112
NOPAT Margin	5.62%	6.31%	17.44%	14.84%	11.47%	17.89%	19.70%	16.08%	18.13%	20.63%
Net Nonoperating Expense Percent (NNEP)	-11.22%	4.29%	1.21%	0.78%	1.56%	2.22%	3.10%	1.31%	0.59%	0.11%
Return On Investment Capital (ROIC_SIMPLE)	3.06%	2.24%	9.66%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	41.10%	34.95%	25.78%	24.97%	27.56%	22.92%	22.36%	23.66%	23.88%	24.29%
SG&A Expenses to Revenue	38.94%	41.02%	42.25%	42.60%	44.96%	45.17%	43.70%	42.11%	39.39%	38.59%
R&D to Revenue	6.50%	7.91%	7.14%	10.16%	10.71%	7.65%	7.78%	6.87%	7.90%	6.67%
Operating Expenses to Revenue	52.31%	56.56%	51.93%	57.08%	58.32%	55.18%	53.89%	50.90%	48.79%	44.09%
Earnings before Interest and Taxes (EBIT)	125	145	229	171	112	173	175	163	154	172
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	620	371	302	244	175	224	219	208	197	200
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.70	1.84	4.02	4.21	4.27	4.17	3.60	4.09	2.86	3.70
Price to Tangible Book Value (P/TBV)	5.78	4.48	4.68	4.91	5.10	4.90	4.37	5.18	3.58	4.49
Price to Revenue (P/Rev)	4.47	4.68	7.25	7.65	8.16	7.45	5.98	6.23	4.22	4.86
Price to Earnings (P/E)	109.36	59.76	38.99	49.11	62.92	37.71	27.24	36.90	22.79	23.49
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.91%	1.67%	2.56%	2.04%	1.59%	2.65%	3.67%	2.71%	4.39%	4.26%
Enterprise Value to Invested Capital (EV/IC)	2.93	1.88	7.16	8.59	7.84	7.53	6.28	6.56	4.21	6.38
Enterprise Value to Revenue (EV/Rev)	4.27	4.57	6.33	6.60	7.16	6.53	5.13	5.55	3.59	4.21
Enterprise Value to EBITDA (EV/EBITDA)	17.33	19.34	21.40	25.93	32.21	22.89	16.74	16.97	10.28	11.50
Enterprise Value to EBIT (EV/EBIT)	86.06	49.34	28.29	36.94	50.47	29.75	20.87	21.62	13.14	13.33
Enterprise Value to NOPAT (EV/NOPAT)	75.91	72.46	36.29	44.45	62.41	36.52	26.05	34.54	19.81	20.40
Enterprise Value to Operating Cash Flow (EV/OCF)	20.65	29.43	36.27	22.88	28.42	29.84	20.15	22.20	13.71	18.50
Enterprise Value to Free Cash Flow (EV/FCFF)	35.92	0.00	690.06	49.47	110.90	122.78	38.24	78.22	0.00	208.08
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.11	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.08	-0.19	-0.54	-0.55	-0.52	-0.51	-0.48	-0.43	-0.46	-0.53
Leverage Ratio	1.26	1.23	1.12	1.12	1.10	1.09	1.10	1.11	1.14	1.18
Compound Leverage Factor	1.22	1.40	1.19	1.18	1.24	1.21	1.19	1.16	1.16	1.19
Debt to Total Capital	9.59%	9.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	9.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	9.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	90.41%	90.55%	100.00%	100.00%	99.99%	100.00%	100.00%	99.99%	99.99%	99.99%
Debt to EBITDA	0.71	1.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-0.83	-0.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	1.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	3.13	4.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-3.62	-1.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	4.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	7.46	5.12	21.53	22.44	24.36	29.39	24.66	24.10	17.59	16.26
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.01%	0.01%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.54	4.88	6.18	6.17	6.80	6.17	6.56	6.67	6.43	6.59
Quick Ratio	1.69	2.60	4.14	4.34	2.72	2.42	3.51	4.01	4.79	4.34
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	299	-2,819	9.38	128	51	42	96	45	-19	11
Operating Cash Flow to CapEx	451.05%	311.09%	241.02%	485.56%	312.28%	243.07%	332.09%	310.04%	361.35%	244.30%
Free Cash Flow to Firm to Interest Expense	71.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	124.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	96.73	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.49	0.44	0.51	0.53	0.49	0.55	0.60	0.63	0.64	0.71
Accounts Receivable Turnover	4.75	4.38	5.42	6.26	5.33	5.39	5.62	6.10	6.65	7.12
Inventory Turnover	1.37	0.96	0.98	1.03	1.02	1.10	1.33	1.36	1.24	1.35
Fixed Asset Turnover	4.39	3.78	4.40	4.38	3.79	4.23	4.53	4.76	4.72	5.91
Accounts Payable Turnover	15.71	11.82	9.09	11.91	10.16	7.13	6.26	7.08	8.06	7.11
Days Sales Outstanding (DSO)	76.85	83.37	67.39	58.31	68.46	67.71	64.95	59.88	54.90	51.29
Days Inventory Outstanding (DIO)	265.67	381.90	370.90	355.62	357.06	332.16	274.38	268.20	295.28	270.59
Days Payable Outstanding (DPO)	23.23	30.89	40.18	30.64	35.93	51.22	58.31	51.57	45.31	51.35
Cash Conversion Cycle (CCC)	319.29	434.38	398.12	383.29	389.59	348.66	281.02	276.51	304.88	270.53
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,664	3,822	904	735	721	681	583	538	481	359
Invested Capital Turnover	0.67	0.66	1.25	1.32	1.13	1.24	1.27	1.25	1.34	1.76
Increase / (Decrease) in Invested Capital	-158	2,918	169	14	40	99	45	57	121	101
Enterprise Value (EV)	10,750	7,167	6,473	6,320	5,650	5,132	3,659	3,531	2,026	2,294
Market Capitalization	11,262	7,343	7,415	7,326	6,436	5,853	4,262	3,961	2,377	2,649
Book Value per Share	$30.68	$29.01	$18.49	$17.16	$15.26	$14.11	$12.04	$10.04	$8.68	$7.51
Tangible Book Value per Share	$14.32	$11.89	$15.88	$14.71	$12.79	$12.02	$9.89	$7.94	$6.93	$6.20
Total Capital	4,621	4,415	1,846	1,741	1,506	1,402	1,186	968	832	715
Total Debt	443	417	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	417	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-513	-176	-942	-1,006	-785	-721	-603	-430	-351	-356
Capital Expenditures (CapEx)	115	78	74	57	64	71	55	51	41	51
Debt-free, Cash-free Net Working Capital (DFCFNWC)	875	1,005	378	281	274	265	195	154	143	155
Debt-free Net Working Capital (DFNWC)	1,765	1,523	824	724	701	576	535	527	434	462
Net Working Capital (NWC)	1,321	1,523	824	724	701	576	535	527	434	462
Net Nonoperating Expense (NNE)	39	-24	-12	-6.99	-12	-15	-16	-5.11	-2.08	-0.38
Net Nonoperating Obligations (NNO)	-513	-176	-942	-1,006	-785	-721	-603	-430	-351	-356
Total Depreciation and Amortization (D&A)	495	225	74	73	63	52	43	45	43	27
Debt-free, Cash-free Net Working Capital to Revenue	34.72%	64.09%	36.96%	29.32%	34.76%	33.69%	27.33%	24.15%	25.37%	28.45%
Debt-free Net Working Capital to Revenue	70.05%	97.10%	80.57%	75.60%	88.84%	73.35%	74.98%	82.91%	76.93%	84.83%
Net Working Capital to Revenue	52.45%	97.10%	80.57%	75.60%	88.84%	73.35%	74.98%	82.91%	76.93%	84.83%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.76	$1.09	$1.89	$1.48	$1.04	$1.57	$1.60	$1.12	$1.09	$1.19
Adjusted Weighted Average Basic Shares Outstanding	135.73M	113.09M	100.47M	100.73M	98.58M	99.15M	97.88M	96.24M	95.65M	95.05M
Adjusted Diluted Earnings per Share	$0.75	$1.07	$1.85	$1.44	$1.01	$1.52	$1.54	$1.10	$1.08	$1.17
Adjusted Weighted Average Diluted Shares Outstanding	137.86M	114.63M	102.64M	103.62M	100.97M	102.00M	101.32M	97.89M	96.43M	96.07M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	137.54M	135.37M	100.30M	101.56M	99.80M	99.84M	98.65M	96.73M	95.97M	95.37M
Normalized Net Operating Profit after Tax (NOPAT)	187	150	185	161	94	144	147	105	106	107
Normalized NOPAT Margin	7.44%	9.56%	18.07%	16.82%	11.89%	18.39%	20.58%	16.50%	18.72%	19.69%
Pre Tax Income Margin	4.79%	10.54%	23.76%	18.83%	15.96%	24.19%	26.45%	26.72%	27.89%	31.72%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	29.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	33.80	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	2.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	6.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	83.30%	183.57%	75.98%	0.00%	102.33%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.41%	6.61%	63.10%	115.93%	119.26%	124.60%	50.95%	10.61%	20.01%	9.79%	10.63%
EBITDA Growth	60.03%	-8.79%	276.51%	105.04%	44.72%	112.89%	-33.21%	-2.02%	16.57%	109.75%	9.54%
EBIT Growth	1,630.42%	-13.50%	1,173.48%	-24.80%	-111.75%	-51.71%	-109.35%	-2.47%	23.10%	219.20%	9.97%
NOPAT Growth	1,161.39%	963.68%	27,385.65%	-35.27%	-87.23%	-86.02%	-99.65%	-2.44%	21.23%	214.05%	-0.36%
Net Income Growth	1,160.31%	76.30%	5,093.99%	-44.97%	-114.49%	-69.97%	-97.90%	5.72%	29.00%	231.42%	0.47%
EPS Growth	1,180.00%	1,800.00%	3,700.00%	-59.65%	-110.42%	-97.92%	-97.87%	7.55%	29.73%	220.00%	4.44%
Operating Cash Flow Growth	238.44%	100.95%	303.40%	54.90%	-1.74%	63.62%	53.35%	-5.03%	19.30%	-16.10%	-57.39%
Free Cash Flow Firm Growth	110.41%	107.64%	103.21%	-2,461.71%	-2,309.60%	-2,220.88%	-3,868.12%	-181.37%	-2,618.06%	-22,053.07%	-268.00%
Invested Capital Growth	-6.06%	-4.12%	-1.37%	296.25%	314.94%	322.59%	350.61%	19.98%	21.59%	22.98%	16.58%
Revenue Q/Q Growth	-9.00%	5.05%	-0.63%	3.80%	-1.60%	60.71%	31.56%	5.39%	0.80%	8.01%	-3.60%
EBITDA Q/Q Growth	19.79%	-24.22%	10.51%	59.52%	-31.72%	212.80%	-39.82%	12.59%	0.44%	-1.87%	-11.71%
EBIT Q/Q Growth	327.58%	-58.74%	15.81%	849.04%	-124.17%	612.09%	-108.11%	17.09%	-0.72%	-0.81%	-15.42%
NOPAT Q/Q Growth	9.03%	48.15%	31.98%	491.69%	-8.06%	3,728.22%	-99.69%	16.69%	0.71%	-5.48%	-12.16%
Net Income Q/Q Growth	184.71%	-48.87%	63.21%	546.26%	-147.34%	1,406.41%	-98.27%	17.47%	-1.87%	5.55%	-13.11%
EPS Q/Q Growth	184.21%	-50.00%	65.22%	560.00%	-600.00%	0.00%	-98.25%	18.75%	0.00%	2.13%	-11.32%
Operating Cash Flow Q/Q Growth	-15.71%	3.28%	275.34%	3.57%	-49.95%	107.34%	44.12%	-34.30%	-16.67%	94.33%	-10.74%
Free Cash Flow Firm Q/Q Growth	36.90%	130.97%	103.35%	1.79%	-0.45%	2.85%	-2,573.02%	7.62%	3.25%	-66.10%	-89.54%
Invested Capital Q/Q Growth	-1.03%	-3.55%	-2.23%	0.66%	1.01%	-0.78%	292.79%	5.41%	2.87%	5.80%	4.58%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.33%	59.92%	56.77%	58.70%	60.19%	56.94%	64.71%	73.78%	74.40%	74.28%	74.23%
EBITDA Margin	29.15%	22.14%	30.70%	27.60%	17.96%	25.88%	13.30%	29.07%	27.21%	27.31%	30.05%
Operating Margin	16.22%	9.17%	7.69%	7.88%	1.32%	1.64%	0.11%	22.71%	20.39%	19.68%	23.49%
EBIT Margin	17.05%	3.63%	9.24%	7.93%	-1.10%	4.47%	-1.40%	22.76%	20.49%	20.80%	22.65%
Profit (Net Income) Margin	12.62%	4.03%	8.28%	5.04%	-1.17%	2.44%	0.26%	19.79%	17.76%	18.24%	18.66%
Tax Burden Percent	72.79%	107.45%	90.89%	66.75%	83.16%	60.15%	39.37%	77.29%	77.75%	80.60%	77.17%
Interest Burden Percent	101.65%	103.42%	98.66%	95.32%	128.42%	90.64%	-47.08%	112.49%	111.46%	108.78%	106.77%
Effective Tax Rate	27.21%	-7.45%	9.11%	33.25%	0.00%	39.85%	60.63%	22.71%	22.25%	19.40%	22.83%
Return on Invested Capital (ROIC)	7.92%	6.63%	4.53%	4.83%	0.73%	0.66%	0.02%	21.41%	19.98%	19.79%	22.79%
ROIC Less NNEP Spread (ROIC-NNEP)	6.06%	17.74%	1.84%	5.08%	3.16%	-0.95%	-0.11%	20.72%	19.46%	19.12%	22.65%
Return on Net Nonoperating Assets (RNNOA)	-0.40%	-1.49%	-0.14%	-0.93%	-0.57%	0.18%	0.02%	-10.61%	-10.54%	-10.38%	-12.32%
Return on Equity (ROE)	7.52%	5.14%	4.39%	3.90%	0.16%	0.84%	0.05%	10.80%	9.44%	9.41%	10.47%
Cash Return on Invested Capital (CROIC)	11.67%	7.99%	3.66%	-117.68%	-119.80%	-119.27%	-121.49%	2.38%	2.46%	1.14%	3.39%
Operating Return on Assets (OROA)	8.87%	1.77%	4.39%	4.92%	-0.59%	1.96%	-0.47%	12.10%	10.56%	10.55%	11.64%
Return on Assets (ROA)	6.56%	1.97%	3.93%	3.13%	-0.63%	1.07%	0.09%	10.52%	9.15%	9.25%	9.59%
Return on Common Equity (ROCE)	7.52%	5.14%	4.39%	3.90%	0.16%	0.84%	0.05%	10.80%	9.44%	9.41%	10.47%
Return on Equity Simple (ROE_SIMPLE)	4.54%	0.00%	2.25%	1.02%	1.70%	0.00%	3.77%	10.29%	10.51%	0.00%	8.80%
Net Operating Profit after Tax (NOPAT)	71	65	44	33	5.60	6.09	0.16	51	44	44	46
NOPAT Margin	11.81%	9.85%	6.99%	5.26%	0.92%	0.99%	0.04%	17.55%	15.85%	15.86%	18.13%
Net Nonoperating Expense Percent (NNEP)	1.86%	-11.11%	2.68%	-0.25%	-2.43%	1.60%	0.13%	0.69%	0.53%	0.67%	0.14%
Return On Investment Capital (ROIC_SIMPLE)	1.73%	1.40%	-	-	-	0.14%	-	-	-	2.36%	-
Cost of Revenue to Revenue	32.67%	40.08%	43.23%	41.30%	39.81%	43.06%	35.29%	26.22%	25.60%	25.72%	25.77%
SG&A Expenses to Revenue	40.59%	38.56%	38.47%	37.82%	41.00%	39.69%	40.72%	41.17%	44.24%	43.01%	41.93%
R&D to Revenue	5.53%	5.08%	5.65%	5.99%	9.44%	8.48%	7.64%	7.32%	7.62%	7.11%	7.36%
Operating Expenses to Revenue	51.11%	50.75%	49.08%	50.82%	58.88%	55.30%	64.60%	51.07%	54.02%	54.60%	50.74%
Earnings before Interest and Taxes (EBIT)	102	24	58	50	-6.66	28	-5.39	66	57	57	58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	174	146	192	174	109	160	51	85	75	75	76
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.46	2.70	2.38	2.33	1.88	1.84	1.19	3.01	2.97	4.02	3.36
Price to Tangible Book Value (P/TBV)	5.35	5.78	5.40	5.59	4.67	4.48	2.77	3.45	3.43	4.68	3.88
Price to Revenue (P/Rev)	4.01	4.47	3.91	4.14	3.89	4.68	4.07	5.45	5.31	7.25	5.94
Price to Earnings (P/E)	54.26	109.36	105.85	227.41	110.93	59.76	31.59	29.24	28.23	38.99	38.19
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.84%	0.91%	0.94%	0.44%	0.90%	1.67%	3.17%	3.42%	3.54%	2.56%	2.62%
Enterprise Value to Invested Capital (EV/IC)	2.65	2.93	2.48	2.36	1.90	1.88	1.21	5.07	5.05	7.16	5.87
Enterprise Value to Revenue (EV/Rev)	3.83	4.27	3.80	4.10	3.86	4.57	3.79	4.53	4.39	6.33	5.03
Enterprise Value to EBITDA (EV/EBITDA)	14.01	17.33	14.84	18.57	18.13	19.34	16.27	15.96	15.00	21.40	19.07
Enterprise Value to EBIT (EV/EBIT)	41.13	86.06	73.21	139.97	89.49	49.34	26.62	20.90	19.62	28.29	26.47
Enterprise Value to NOPAT (EV/NOPAT)	47.29	75.91	107.53	219.93	121.58	72.46	33.70	26.90	25.25	36.29	33.78
Enterprise Value to Operating Cash Flow (EV/OCF)	14.88	20.65	22.69	34.99	30.22	29.43	22.94	26.83	25.10	36.27	26.31
Enterprise Value to Free Cash Flow (EV/FCFF)	21.98	35.92	67.19	0.00	0.00	0.00	0.00	231.97	225.65	690.06	186.19
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.11	0.11	0.11	0.11	0.10	0.10	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.10	0.10	0.00	0.00	0.00	0.00
Financial Leverage	-0.07	-0.08	-0.07	-0.18	-0.18	-0.19	-0.21	-0.51	-0.54	-0.54	-0.54
Leverage Ratio	1.21	1.26	1.26	1.21	1.22	1.23	1.23	1.12	1.12	1.12	1.12
Compound Leverage Factor	1.23	1.31	1.25	1.15	1.56	1.11	-0.58	1.26	1.25	1.22	1.19
Debt to Total Capital	0.00%	9.59%	9.70%	9.77%	9.76%	9.45%	8.91%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	9.59%	9.70%	9.77%	9.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	9.45%	8.91%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	90.41%	90.30%	90.23%	90.24%	90.55%	91.09%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.71	0.69	0.87	1.05	1.13	1.43	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	-0.83	-0.43	-0.18	-0.15	-0.47	-1.17	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	1.13	1.43	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	3.13	4.99	10.34	7.03	4.22	2.97	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	-3.62	-3.08	-2.17	-1.02	-1.78	-2.43	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	4.22	2.97	0.00	0.00	0.00	0.00
Altman Z-Score	10.95	7.39	6.84	6.51	5.27	5.05	3.47	17.78	16.45	21.26	18.66
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.45	2.54	2.51	2.42	2.33	4.88	4.47	7.80	6.39	6.18	6.33
Quick Ratio	2.59	1.69	1.57	1.39	1.23	2.60	2.25	5.50	4.34	4.14	4.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	304	222	96	-2,872	-2,925	-2,912	-2,997	-112	-121	-125	-76
Operating Cash Flow to CapEx	491.09%	1,229.26%	485.45%	195.19%	183.38%	457.47%	234.44%	196.04%	333.39%	348.83%	274.72%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	124.25	-1,230.10	-1,544.17	-1,128.09	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	262.78	23.24	27.66	40.56	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	208.65	11.33	12.58	31.69	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.52	0.49	0.47	0.62	0.54	0.44	0.33	0.53	0.52	0.51	0.51
Accounts Receivable Turnover	4.70	4.75	4.58	5.25	5.02	4.38	3.50	5.07	5.50	5.42	5.46
Inventory Turnover	1.34	1.37	1.28	1.63	1.26	0.96	0.60	0.94	0.96	0.98	0.99
Fixed Asset Turnover	4.42	4.39	4.22	5.46	4.61	3.78	2.91	4.51	4.52	4.40	4.42
Accounts Payable Turnover	16.01	15.71	14.36	17.87	15.92	11.82	5.94	8.33	8.35	9.09	9.68
Days Sales Outstanding (DSO)	77.73	76.85	79.68	69.52	72.78	83.37	104.23	72.04	66.41	67.39	66.88
Days Inventory Outstanding (DIO)	272.96	265.67	285.43	223.68	288.72	381.90	613.39	387.43	381.01	370.90	369.95
Days Payable Outstanding (DPO)	22.80	23.23	25.41	20.42	22.93	30.89	61.43	43.80	43.69	40.18	37.69
Cash Conversion Cycle (CCC)	327.89	319.29	339.70	272.78	338.57	434.38	656.19	415.67	403.73	398.12	399.14
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,627	3,664	3,800	3,886	3,861	3,822	3,852	981	930	904	855
Invested Capital Turnover	0.67	0.67	0.65	0.92	0.79	0.66	0.52	1.22	1.26	1.25	1.26
Increase / (Decrease) in Invested Capital	-234	-158	-53	2,905	2,930	2,918	2,997	163	165	169	122
Enterprise Value (EV)	9,607	10,750	9,417	9,160	7,330	7,167	4,653	4,970	4,697	6,473	5,019
Market Capitalization	10,068	11,262	9,687	9,250	7,391	7,343	4,988	5,974	5,681	7,415	5,928
Book Value per Share	$29.72	$30.68	$30.05	$29.44	$28.98	$29.01	$41.68	$19.78	$19.09	$18.49	$17.73
Tangible Book Value per Share	$13.69	$14.32	$13.26	$12.26	$11.70	$11.89	$17.95	$17.25	$16.52	$15.88	$15.36
Total Capital	4,088	4,621	4,507	4,407	4,346	4,415	4,597	1,985	1,915	1,846	1,764
Total Debt	0.00	443	437	430	424	417	410	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	417	410	0.00	0.00	0.00	0.00
Net Debt	-461	-513	-270	-90	-62	-176	-335	-1,004	-984	-942	-909
Capital Expenditures (CapEx)	36	17	42	28	29	23	22	18	16	18	12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	864	875	981	1,067	1,032	1,005	1,020	442	399	378	369
Debt-free Net Working Capital (DFNWC)	1,325	1,765	1,676	1,560	1,466	1,523	1,489	1,055	903	824	775
Net Working Capital (NWC)	1,325	1,321	1,238	1,130	1,042	1,523	1,489	1,055	903	824	775
Net Nonoperating Expense (NNE)	-4.85	38	-8.12	1.36	13	-8.95	-0.84	-6.54	-5.28	-6.52	-1.36
Net Nonoperating Obligations (NNO)	-461	-513	-270	-90	-62	-176	-335	-1,004	-984	-942	-909
Total Depreciation and Amortization (D&A)	72	122	134	124	116	132	56	18	19	18	19
Debt-free, Cash-free Net Working Capital to Revenue	34.42%	34.72%	39.57%	47.72%	54.35%	64.09%	83.14%	40.29%	37.28%	36.96%	37.01%
Debt-free Net Working Capital to Revenue	52.79%	70.05%	67.60%	69.76%	77.24%	97.10%	121.38%	96.16%	84.46%	80.57%	77.60%
Net Working Capital to Revenue	52.79%	52.45%	49.97%	50.51%	54.90%	97.10%	121.38%	96.16%	84.46%	80.57%	77.60%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.55	$0.20	$0.38	$0.23	($0.05)	$0.02	$0.01	$0.57	$0.49	$0.50	$0.48
Adjusted Weighted Average Basic Shares Outstanding	136.76M	135.73M	135.62M	135.20M	135.36M	113.09M	113.54M	100.37M	100.28M	100.47M	99.65M
Adjusted Diluted Earnings per Share	$0.54	$0.19	$0.38	$0.23	($0.05)	$0.01	$0.01	$0.57	$0.48	$0.48	$0.47
Adjusted Weighted Average Diluted Shares Outstanding	139.77M	137.86M	138.06M	136.98M	135.36M	114.63M	115.25M	101.78M	102.20M	102.64M	101.42M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	135.38M	137.54M	136.17M	135.41M	135.06M	135.37M	137.79M	100.46M	100.33M	100.30M	99.84M
Normalized Net Operating Profit after Tax (NOPAT)	71	54	45	43	21	16	34	53	45	50	46
Normalized NOPAT Margin	11.93%	8.21%	7.12%	6.80%	3.41%	2.53%	8.93%	18.33%	16.23%	18.15%	17.93%
Pre Tax Income Margin	17.33%	3.75%	9.11%	7.56%	-1.41%	4.05%	0.66%	25.61%	22.84%	22.63%	24.18%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	74.59	21.38	-3.52	10.68	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	56.41	14.19	2.96	2.36	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	20.46	9.47	-18.60	1.82	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	2.28	2.28	-12.13	-6.51	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	103.97%	83.30%	339.13%	763.00%	463.59%	183.57%	0.00%	0.00%	0.00%	75.98%	93.09%

Frequently Asked Questions About Globus Medical's Financials

When does Globus Medical's fiscal year end?

According to the most recent income statement we have on file, Globus Medical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Globus Medical's net income changed over the last 9 years?

Globus Medical's net income were at $102.98 million at the end of 2024, a 16.2% decrease from 2023, and a 8.7% decrease since 2015. View Globus Medical's forecast to see where analysts expect Globus Medical to go next.

What is Globus Medical's operating income?

Globus Medical's total operating income in 2024 was $165.99 million, based on the following breakdown:

Total Gross Profit: $1.48 billion
Total Operating Expenses: $1.32 billion

How has Globus Medical revenue changed over the last 9 years?

Over the last 9 years, Globus Medical's total revenue changed from $544.75 million in 2015 to $2.52 billion in 2024, a change of 362.5%.

How much debt does Globus Medical have?

Globus Medical's total liabilities were at $1.07 billion at the end of 2024, a 1.3% decrease from 2023, and a 804.6% increase since 2015.

How much cash does Globus Medical have?

In the past 9 years, Globus Medical's cash and equivalents has ranged from $0.00 in 2017 to $784.44 million in 2024, and is currently $784.44 million as of their latest financial filing in 2024.

How has Globus Medical's book value per share changed over the last 9 years?

Over the last 9 years, Globus Medical's book value per share changed from 7.51 in 2015 to 30.68 in 2024, a change of 308.5%.

Related Companies

This page (NYSE:GMED) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Financials

Frequently Asked Questions About Globus Medical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Financials

Annual Income Statements for Globus Medical

Quarterly Income Statements for Globus Medical

Annual Cash Flow Statements for Globus Medical

Quarterly Cash Flow Statements for Globus Medical

Annual Balance Sheets for Globus Medical

Quarterly Balance Sheets for Globus Medical

Annual Metrics And Ratios for Globus Medical

Quarterly Metrics And Ratios for Globus Medical

Frequently Asked Questions About Globus Medical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools